Effect of Topical Prostaglandin F2α Analogs on Selected Oxidative Stress Parameters in the Tear Film

Effect of Topical Prostaglandin F2α Analogs on Selected Oxidative Stress Parameters in the Tear Film

<i>Background and Objectives</i>: Topically administered antiglaucoma medications, especially those containing benzalkonium chloride (BAC), may cause local adverse effects and compromise ocular surface. The aim of the study was to assess the effect of topical prostaglandin F2α a...

Full description

Bibliographic Details
Main Authors:	Lech Sedlak, Maria Zych, Weronika Wojnar, Dorota Wyględowska-Promieńska
Format:	Article
Language:	English
Published:	MDPI AG 2019-07-01
Series:	Medicina
Subjects:	glaucoma ocular surface benzalkonium chloride latanoprost tafluprost bimatoprost tears
Online Access:	https://www.mdpi.com/1010-660X/55/7/366

Similar Items

Long-term assessment of prostaglandin analogs and timolol fixed combinations vs prostaglandin analogs monotherapy
by: Ai-Wei Liu, et al.
Published: (2016-05-01)

Determination of five prostaglandin analogs in eyelash enhancing cosmetics by LC-MS/MS
by: XU Yong, et al.
Published: (2022-02-01)

Effect of Topical Prostaglandin Analogue Therapy on Central Corneal Thickness: A Systematic Review
by: Jae-Yun Kim, et al.
Published: (2022-12-01)

Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a Meta-analysis
by: Xi-Ting Yang, et al.
Published: (2020-03-01)

Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film
by: Lech Sedlak, et al.
Published: (2021-09-01)

Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients
by: Nicholas Brennan, et al.
Published: (2017-08-01)

Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial [Corrigendum]
by: Bacharach J, et al.
Published: (2023-09-01)

Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial
by: Bacharach J, et al.
Published: (2023-09-01)

Long-Term Effectiveness and Safety of Tafluprost, Travoprost, and Latanoprost in Korean Patients with Primary Open-Angle Glaucoma or Normal-Tension Glaucoma: A Multicenter Retrospective Cohort Study (LOTUS Study)
by: Joon-Mo Kim, et al.
Published: (2021-06-01)

The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis
by: Shangxuan Jiang, et al.
Published: (2023-03-01)

Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost
by: Joon Mo Kim, et al.
Published: (2021-05-01)

Physiochemical Properties and Cytotoxicity of a Benzalkonium Chloride-Free, Micellar Emulsion Ophthalmic Formulation of Latanoprost
by: Halder A, et al.
Published: (2020-10-01)

Prostaglandin analogs in ophthalmology
by: S Subbulakshmi, et al.
Published: (2023-01-01)

Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease
by: Sang-Woo Park, et al.
Published: (2022-02-01)

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
by: Ruangvaravate N, et al.
Published: (2020-10-01)

Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma
by: Sherein M Hagras, et al.
Published: (2021-01-01)

Efficacy and safety of newly developed preservative-free latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized, multicenter, controlled phase III trial
by: Joon Mo Kim, et al.
Published: (2021-10-01)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
by: Lee D, et al.
Published: (2017-07-01)

Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin analog/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension
by: Tamçelik N, et al.
Published: (2017-04-01)

Comparison of the Efficacy of Latanoprost, Bimatoprost, and Travoprost in Patients with Primary Open-Angle Glaucoma and Ocular Hypertension
by: Nur Çolak, et al.
Published: (2014-05-01)

Efficacy and Adverse Effects of Topical Latanoprost with Respect to Preservative in Patients of POAG
by: Gyanendra Kumar, et al.
Published: (2018-08-01)

Aging and topical pilocarpine concentrations effects on pupil size and tear flow rate
by: Michael O. Emina
Published: (2010-04-01)

Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
by: Mylla Boso AL, et al.
Published: (2020-01-01)

Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
by: Mariaelena Filippelli, et al.
Published: (2022-06-01)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
by: Pillunat LE, et al.
Published: (2016-09-01)

Ophthalmic Bimatoprost-Loaded Niosomal In Situ Gel: Preparation, Optimization, and In Vivo Pharmacodynamics Study
by: Mohammed F. Aldawsari, et al.
Published: (2023-11-01)

Short-term efficacy analysis of domestic and imported prostaglandins on treating open angle glaucoma
by: Zhen-Chao Chen, et al.
Published: (2016-02-01)

Efficacy of preserved Tafluprost 0.0015% in lowering intraocular pressure
by: Chandrima Paul
Published: (2023-01-01)

Therapeutic Effects of Sodium Hyaluronate on Ocular Surface Damage Induced by Benzalkonium Chloride Preserved Anti-glaucoma Medications
by: Xing Liu, et al.
Published: (2015-01-01)

Prevalence of Ocular Surface Disease and Associated Risk Factors in Glaucoma Patients: A Survey Study of Ophthalmologists
by: Nilgün Yıldırım, et al.
Published: (2022-10-01)

Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension
by: Xu KM, et al.
Published: (2022-07-01)

Real-life results of switching from preserved to preservative-free artificial tears containing hyaluronate in patients with dry eye disease
by: Nasser L, et al.
Published: (2018-08-01)

The evaluation of the effect of tafluprost on the intraocular pressure of healthy male guinea pigs under different light‐and‐darkness regimes
by: Arghavan Armin, et al.
Published: (2023-05-01)

Safety profile of 0.0015% tafluprost eye drops in China: a post-marketing observational study
by: Xue-Li Chen, et al.
Published: (2023-01-01)

Efficacy and Tolerability of a New Latanoprost 0.005% BAK-Free Nanoemulsion: A Nonrandomized Open-Label Trial
by: Javier F. Casiraghi, et al.
Published: (2021-01-01)

The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations
by: Ruiz Simonato Alonso, et al.
Published: (2020-03-01)

Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin-Timolol Combination: A Prospective Real-Life Study
by: Jandroković S, et al.
Published: (2022-09-01)

Use Pattern of Ophthalmic Antiglaucoma Agents with and without Preservatives: A Cross-Sectional Study
by: Luis Fernando Valladales-Restrepo, et al.
Published: (2023-05-01)

High Performance Liquid Chromatography Tandem Mass Spectrometry Measurement of Bimatoprost, Latanoprost and Travoprost in Eyelash Enhancing Cosmetic Serums
by: Emilia Marchei, et al.
Published: (2016-02-01)

Effect of latanoprost on open angle glaucoma
by: Min Zhang, et al.
Published: (2018-06-01)